ALNY vs VALU · P/E 76, rev $1.29B vs P/E 15, rev $33.4M
Alnylam Pharmaceuticals Inc (ALNY) versus Value Line Inc (VALU) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Value Line Inc (VALU) is a financial data & stock exchanges company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported VALU revenue for 2026-04-30 was $33.4M. Net income was $21.6M. Revenue was down 4.7% from 2025-04-30 to 2026-04-30. VALU currently screens at market cap $324.4M and trailing P/E 14.8.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. VALU currently screens at market cap $324.4M and trailing P/E 14.8.
Not investment advice. Open the ALNY and VALU stock pages for the full models.
Not investment advice.